| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Regeneron |
| Recipient: You |
| Company: Inovio Pharmaceuticals |
| Recipient: You |
| Company: Merck |
| Recipient: Your Institution |
| Company: Ellipses Pharma |
| Recipient: Your Institution |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: GlaxoSmithKline |
| Recipient: Your Institution |
| Company: Millennium |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Aeterna Zentaris |
| Recipient: Your Institution |
| Company: Novartis |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: Tesaro |
| Recipient: Your Institution |
| Company: Cerulean Pharma |
| Recipient: Your Institution |
| Company: Aduro Biotech |
| Recipient: Your Institution |
| Company: Advaxis |
| Recipient: Your Institution |
| Company: Syndax |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Genentech/Roche |
| Recipient: Your Institution |
| Company: Cerulean Pharma |
| Recipient: Your Institution |
| Company: Morab |
| Recipient: Your Institution |
| Company: Morphotek |
| Recipient: Your Institution |
| Company: Syndax |
| Recipient: Your Institution |
| Company: Ludwig Institute for Cancer Research |
| Recipient: Your Institution |
| Company: Leap Therapeutics |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: UpToDate |
| Recipient: You |
| Please describe: Editor, British Journal of Ob/Gyn |
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|